Pharma Forges Ahead With ICH Q12 Preparations Despite Misgivings
Executive Summary
While reservations are still being expressed on ICH Q12, the pharmaceutical industry is busily preparing for ICH Q12 implementation.
You may also be interested in...
Final ICH Q12 Post-Approval Changes Guideline Expected In November
A final revision of the ICH Q12 lifecycle management guideline is expected to overcome a conflict with EU variations legislation and offer more clarity on what is, and what is not, an established condition subject to post-approval change reporting requirements.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.